Inventiveness in peptide drug technology and a well thought- out business strategy characterize PeptiDream’s thriving growth. Venture Valuation (VV) interviewed Kiichi Kubota, co-founder and Chairman. Read the interview
Assessing the Valuation of New Ventures – MassChallengeCH, Lausanne, September 2017
Venture Valuation CEO, Dr. Patrik Frei is one of the experts working as mentors for MassChallengeCH, a famous startup accelerator. He helps new entrepreneurs understand the concepts and meaning of company valuation. Below, you can find a link to the notes from his workshop about assessing a company prior to valuation. Assessing the Valuation of New … Continue reading Assessing the Valuation of New Ventures – MassChallengeCH, Lausanne, September 2017
Venture Valuations Biotechgate Collaborates with California Life Sciences Association (CLSA) to Connect California’s Life Sciences Sector
Zurich, Bay Area & San Diego, CA – August 2017 – California Life Sciences Association (CLSA), the premier public policy advocacy and business leadership trade association representing California’s life sciences industry, and Venture Valuations Biotechgate, a global Life Sciences database today announced their collaboration to create an in-depth member directory for CLSA as well as a … Continue reading Venture Valuations Biotechgate Collaborates with California Life Sciences Association (CLSA) to Connect California’s Life Sciences Sector
Whitepaper: Focus on the Antibiotics Market
The antibiotics market is expected to reach USD 57.0 billion by 2024. Rising prevalence of infectious diseases is contributing to the market growth, especially in developing regions such as Asia-Pacific. However, raising capital for companies active in this field has been difficult for the past few years. Thus, Venture Valuation has collected some important facts, … Continue reading Whitepaper: Focus on the Antibiotics Market
Valuation of Life Sciences Start-up – Questions and Answers
Last month, CEO of Venture Valuation, Dr Patrik Frei, delivered a live webinar titled ‘Valuation of Life Sciences Start-up’ to healthcare alumni of Harvard Business School You can watch the webinar here. Due to a large number of questions from participants, not all of them could be answered during the event. In this post, we … Continue reading Valuation of Life Sciences Start-up – Questions and Answers
Dr. Patrik Frei Delivers a Webinar to Harvard Business School Alumni
On 7th of June 2017, CEO of Venture Valuation, Dr Patrik Frei, delivered a live webinar titled ‘Valuation of Life Sciences Start-up’ to healthcare alumni of Harvard Business School. The online event was a part of Healthcare Roundtable, a series of interactive presentations by industry leaders organised by HBS Healthcare Alumni Association. Dr. Frei talked about the significance … Continue reading Dr. Patrik Frei Delivers a Webinar to Harvard Business School Alumni
Interviews with leading Life Sciences companies: GeNeuro SA
By leveraging expertise it has built up over decades in the HERV medical research and development, GeNeuro is engaging in unprecedented therapeutic development targeting HERVs. Venture Valuation (VV) interviewed Jesús Martin-Garcia, co-founder and CEO Read the interview.
RESI Conference June 2017- Deal and Product Valuations Workshop
Dr. Patrik Frei, Venture Valuation CEO and a worldwide known expert in life sciences company and product valuation, delivered a workshop on the topic during he Redefining Early Stage Investments Conference in San Diego. The notes from the workshop are available to download here.
New Record in Valuation of Life Sciences Companies and Products
Zurich / Singapore / Boston, March 2017 – Venture Valuation is looking back to a new record year in terms of valuations. The past year has seen a new record number of valuations provided by Venture Valuation to its clients with 45 valuations in 2016 compared to 31 in 2015. Over the two year period, … Continue reading New Record in Valuation of Life Sciences Companies and Products
Interviews with leading Life Sciences companies: ObsEva SA
ObsEva is specialized in re energizing women’s reproductive and pregnancy therapeutics that have been overlooked and underserved for years. Venture Valuation (VV) interviewed Dr. Ernest Loumaye, co-founder and CEO. Read the interview